PROFIL HEMATOLOGI PENANDA ANEMIA PADA PENDERITA TUBERKULOSIS DENGAN PENGOBATAN DI PUSKESMAS PUUWATU KOTA KENDARI

Bagcchi, S. (2023). WHO’s global tuberculosis report 2022. The Lancet Microbe, 4(1), e20.

Chhabra, S., Kashyap, A., Bhagat, M., Mahajan, R., & Sethi, S. (2021). Anemia and nutritional status in tuberculosis patients. International Journal of Applied and Basic Medical Research, 11(4), 226–230.

Gelaw, Y., Getaneh, Z., & Melku, M. (2021). Anemia as a risk factor for tuberculosis: a systematic review and meta-analysis. Environmental Health and Preventive Medicine, 26, 1–15.

Hutauruk, D. (2021). Gambaran Nilai Hematokrit Pasien Tuberculosis Yang Mendapat Pengobatan Obat Anti Tuberculosis (Oat) Di Puskesmas Raya Pematangsiantar. Klinikal Sains: Jurnal Analis Kesehatan, 9(1), 36–46.

Isanaka, S., Mugusi, F., Urassa, W., Willett, W. C., Bosch, R. J., Villamor, E., Spiegelman, D., Duggan, C., & Fawzi, W. W. (2012). Iron Deficiency and Anemia Predict Mortality in Patients with Tuberculosis3. The Journal of Nutrition, 142(2), 350–357.

Istiantoro, Y. H., & Setiabudy, R. (2012). Tuberkulostatik dan Leprostatik. Pada: Farmakologi Dan Terapi, Edisi, 5, 613–632.

Kassa, E., Enawgaw, B., Gelaw, A., & Gelaw, B. (2016a). Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia. BMC Hematology, 16, 1–11.

Kassa, E., Enawgaw, B., Gelaw, A., & Gelaw, B. (2016b). Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia. BMC Hematology, 16(1), 1–11. https://doi.org/10.1186/s12878-015-0037-1

Kemenkes, R. I. (2020). Pedoman Nasional Pelayanan Kedokteran: Tatalaksana Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia.

Koju, D., Rao, B. S., Shrestha, B., Shakya, R., & Makaju, R. (2005). Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment. Kathmandu University J Sci Eng Technol, 1(1), 1–2.

Mintzer, D. M., Billet, S. N., & Chmielewski, L. (2009). Drug-induced hematologic syndromes. Advances in Hematology, 2009.

Muzaffar, T. M., Shaifuzain, A. R., Imran, Y., & Haslina, M. N. (2008). Hematological changes in tuberculous spondylitis patients at the Hospital Universiti Sains Malaysia. Southeast Asian J Trop Med Public Health, 39(4), 686–689.

Nagayama, N., Shishido, Y., Masuda, K., Baba, M., Tamura, A., Nagai, H., Akagawa, S., Kawabe, Y., Machida, K., & Kurashima, A. (2004). Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid. Kekkaku (Tuberculosis), 79(5), 341–348.

Nagu, T. J., Spiegelman, D., Hertzmark, E., Aboud, S., Makani, J., Matee, M. I., Fawzi, W., & Mugusi, F. (2014). Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmonary tuberculosis patients in Dar-es-Salaam, Tanzania. PloS One, 9(3), e91229.

Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. The Journal of Clinical Investigation, 113(9), 1271–1276.

Olaniyi, J. A., & Aken’Ova, Y. A. (2003). Haematological profile of patients with pulmonary tuberculosis in Ibadan, Nigeria. African Journal of Medicine and Medical Sciences, 32(3), 239–242.

Tenggara, D. P. S. (2020). Profil Kesehatan Sulawesi Tenggara. Kendari.

Thuraidah, A., Astuti, R. A. W., & Rakhmina, D. (2017). Anemia dan Lama Konsumsi Obat Anti Tuberculosis. Medical Laboratory Technology Journal, 3(2), 42–46.

Tozkoparan, E., Deniz, O., Ucar, E., Bilgic, H., & Ekiz, K. (2007). Changes in platelet count and indices in pulmonary tuberculosis.

Weiss, G. (2002). Pathogenesis and treatment of anaemia of chronic disease. Blood Reviews, 16(2), 87–96.

Yaranal, P. J., Umashankar, T., & Harish, S. G. (2013). Hematological profile in pulmonary tuberculosis. Int J Health Rehabil Sci, 2(1), 50–55.